Tuberc Respir Dis.  1981 Dec;28(4):145-149. 10.4046/trd.1981.28.4.145.

Clinical Experience of Short-Course Chemotherapy for Pulmonary Tuberculosis

• KMID: 2528843
• DOI: http://doi.org/10.4046/trd.1981.28.4.145

Abstract

A clinical trial was made on 100 pulmonary tuberculosis patients with the regimen of SHRZ for 9months (study group) and SHE or SHP for 18months (control group). Each group was consisted of 50 patients. Treatment failure rate was 6% in control group, 0% in study group. Postchemotherapy 6 month follow up rate was 82% vs 92%, 1 year follow up rate was 46% vs. 72 %, showing better patient compliance in study group. The relapse rate was 2. 4% vs 2. 2% in 6 month and 21. 8% vs. 8.3 % in 1 year, showing better result in study group. The side effect was more frequent in study group, which was mainly hepatotoxicity, (56% in study group vs. 10% in control group). In conclusion, we suggest that short-course chemotherapy with SHRZ shows better treatment result, better patient compliance and lower relapse rate, but significantly high complication rate.